Michael E. Hurwitz, PhD, MD

Assistant Professor of Medicine (Medical Oncology)

Clinical Interests

  • Adult
  • Urinary Bladder Neoplasms
  • Kidney Neoplasms
  • Medical Oncology
  • Prostatic Neoplasms
  • Testicular Neoplasms

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From physicians only

Patient Care Organizations

Cancer Center, Yale: Prostate and Urologic Cancers Program

General Urology

Medical Oncology: Subset Medical Oncology Faculty

Medical Oncology

Yale Medical Group

Board Certifications

  • Medical Oncology AB of Internal Medicine (2004)

Clinical Trials

Conditions Study Title
Melanoma, skin Refractory B7-H3-Expressing Neoplasms and Neoplasms whose Vasculature Exhibits B7-H3 Neoplasms
Colon, Melanoma, skin Phase 1 Study of CM-24 in Subjects with Selected Advanced or Recurrent Malignancies
Soft Tissue Phase 1 study of safety & pharmacology with locally advanced or metastatic solid tumors
Melanoma, skin Varlilumab and Nivolumab in advanced refractory solid tumors
Soft Tissue Phase 1 Study of Mogamulizumab (KW-0761) in Combination with MEDI4736 & Mogamulizumab in Combinati
Bladder S1011: Standard or Extended Pelvic Lymphadenectomy in Pts to have Surgery for Invasive Bladder Canc
Bladder Novartis BGJ398: A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
Melanoma, skin Stand Up To Cancer
Other Skin Merkel Cell Carcinoma (MCC) Therapy with MK-3475
Kidney A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monot
Kidney S0931: Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Melanoma, skin PF-05082566 + MK-3475 IN ADVANCED SOLID TUMORS
Lung, Melanoma, skin Phase 2 Study of MK-3475 in Patients with Melanoma or NSCLC with Untreated Brain Mets
Prostate Medivation (PROSPER): Phase 3 Randomized, Double-Blind Study of Enzalutamide for Nonmetastatic CRPC
Bladder, Other Urinary ASG-22CE-13-2: A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE
Prostate Bayer 16544: randomized phase IIa study of RAD-223 w/ abiraterone or enzalutamide
Prostate SWOG S1216: Phase III RCT for mCRPC pts comparing ADT and TAK700 with ADT and Bicalutamide
Melanoma, skin Phase 1 Open label, Dose Finding Study of IMCgp100 in Patients with Advanced Malignant Melanoma
Melanoma, skin AdaptImmune Phase I/II Melanoma Trial
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, Thyroid PCD4989g: Phase I, Open-label MPDL3280A in solid tumors

Edit this profile

Contact Info

Michael E. Hurwitz, PhD, MD
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste North Pavilion 4

New Haven, CT 06510
View on map...
Mailing Address
PO Box 208032
New Haven, CT 06520